No Data
No Data
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation
William Blair Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating
Optimistic Outlook for Tenaya Therapeutics Amid Positive Trial Developments for TN-201
TD Cowen Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating
Leerink Partners Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $8
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $19
No Data
No Data